TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT04037891

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Cause of deathFunding or business, also safety Automatic label, confidence 0.5, unverified. How labels are made.
“The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576.”

The sponsor’s own words in the registry.

Life of this trial

20192020202120222023202420252026Registered2019-02-13Started2019-03-04Stopped2020-04-30Results posted2025-02-27

Vital statistics

Status
Terminated
Phase
Phase 1, Phase 2
Sponsor
AKARI Therapeutics
Sponsor type
Industry
Conditions
Keratoconjunctivitis, Atopic; Keratoconjunctivitis, Vernal; Conjunctivitis, Allergic
Interventions
rVA576; Placebo; rVA576
Participants
12
Sites
9
Countries
Spain, United Kingdom

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.